Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
Director departure
Appointed director
CC transcript
Auditor change
|
|
Vaxart, Inc. (VXRT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 07/07/2023 |
SC 13G/A
| BlackRock Inc. reports a 1.3% stake in Vaxart, Inc. |
| 01/10/2023 |
SC 13G/A
| STATE STREET CORP reports a 1.8% stake in EXIT FILING VAXART INC |
| 03/10/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/11/2022 |
SC 13G/A
| STATE STREET CORP reports a 8.9% stake in AMENDED FILING VAXART INC |
| 02/10/2020 |
SC 13G/A
| BML Investment Partners, L.P. reports a 3.5% stake in Vaxart, Inc. |
| 02/13/2018 |
SC 13G/A
| Broadfin Capital, LLC reports a 0% stake in Aviragen Therapeutics, Inc. |
| 02/13/2017 |
SC 13G/A
| Broadfin Capital, LLC reports a 9% stake in Aviragen Therapeutics, Inc. |
| 02/13/2017 |
SC 13G/A
| SENZAR ASSET MANAGEMENT, LLC reports a 4.6% stake in Aviragen Therapeutics, Inc. |
| 02/16/2016 |
SC 13G/A
| Krensavage Asset Management, LLC reports a 6.8% stake in Biota Pharmaceuticals, Inc. |
| 02/11/2016 |
SC 13G/A
| Broadfin Capital, LLC reports a 9% stake in Biota Pharmaceuticals, Inc. |
| 02/10/2016 |
SC 13G/A
| CLAY LANDON T reports a 8.8% stake in Biota Pharmaceuticals, Inc. |
| 02/17/2015 |
SC 13G/A
| Broadfin Capital, LLC reports a 7.4% stake in Biota Pharmaceuticals, Inc. |
| 02/11/2015 |
SC 13G/A
| CLAY LANDON T reports a 9.7% stake in Biota Pharmaceuticals, Inc. |
| 01/29/2014 |
SC 13G/A
| CLAY LANDON T reports a 10.8% stake in Biota Pharmaceuticals, Inc. |
| 12/05/2013 |
SC 13G/A
| Hunter Hall Investment Management LTD reports a 3.6% stake in Biota Pharmaceuticals Inc |
| 11/14/2013 |
SC 13G/A
| Mangrove Partners Fund, L.P. reports a 0% stake in BIOTA PHARMACEUTICALS, INC. f/k/a NABI BIOPHARMACEUTICALS |
| 07/25/2013 |
SC 13G/A
| Hunter Hall Investment Management LTD reports a 7.3% stake in Biota Pharmaceuticals Inc |
| 02/13/2013 |
SC 13G/A
| CLAY LANDON T reports a 11.3% stake in Biota Pharmaceuticals, Inc. |
| 02/12/2013 |
SC 13G/A
| RENAISSANCE TECHNOLOGIES LLC reports a 1.1% stake in Biota Pharmaceuticals, Inc. |
| 02/12/2013 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2012 |
SC 13G/A
| NABI BIOPHARMACEUTICALS reports a 0.6% stake in Nabi Biopharmaceuticals |
| 02/13/2012 |
SC 13G/A
| NABI BIOPHARMACEUTICALS reports a 5.6% stake in NABI BIOPHARMACEUTICALS |
| 02/13/2012 |
SC 13G/A
| NABI BIOPHARMACEUTICALS reports a 6.5% stake in Nabi Biopharmaceuticals |
| 02/08/2012 |
SC 13G/A
| NABI BIOPHARMACEUTICALS reports a 5.4% stake in Nabi Biopharmaceuticals |
| 08/10/2011 |
SC 13G/A
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals [amend] |
| 02/14/2011 |
SC 13G/A
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals [amend] |
| 02/11/2011 |
SC 13G/A
| NABI BIOPHARMACEUTICALS reports a 5.6% stake in Nabi Biopharmaceuticals |
| 02/07/2011 |
SC 13G/A
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals [amend] |
| 06/22/2010 |
SC 13G/A
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals [amend] |
| 02/12/2010 |
SC 13G/A
| NABI BIOPHARMACEUTICALS reports a 5.6% stake in Nabi Biopharmaceuticals |
|
|